Literature DB >> 7191780

cis-Dichlorodiammineplatinum(II) in the treatment of esophageal carcinoma.

S Davis, M Shanmugathasa, W Kessler.   

Abstract

Seventeen consecutive patients with untreated squamous cell carcinoma of the esophagus were treated with cis-dichlorodiammineplatinum(II) (DDP) by infusion at a dose of 3 mg/kg with mannitol diuresis. One patient had a partial response and six additional patients had subjective improvement in dysphagia and associated weight gain; however, no complete responses were noted. Toxic effects were mainly renal. There were no drug-related deaths. We conclude that DDP alone is not effective in squamous cell carcinoma of the esophagus.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7191780

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

Review 1.  Update in cancer chemotherapy: gastrointestinal cancer, cancer of the small intestines, gallbladder, liver, and esophagus.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-08       Impact factor: 1.798

2.  13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial.

Authors:  C F Slabber; G Falkson; W Burger; L Schoeman
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus (E2298): A Trial of the Eastern Cooperative Oncology Group.

Authors:  Joanne F Rossman; Carla I Falkson; Ronghui Xu; Coenraad F Slabber; Bernard A Mason; Mary F Mulcahy; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2011-01

4.  Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer.

Authors:  K Kolarić; A Roth
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 5.  Molecular mechanisms associated with chemoresistance in esophageal cancer.

Authors:  Matheus Lohan-Codeço; Maria Luísa Barambo-Wagner; Luiz Eurico Nasciutti; Luis Felipe Ribeiro Pinto; Nathalia Meireles Da Costa; Antonio Palumbo
Journal:  Cell Mol Life Sci       Date:  2022-02-03       Impact factor: 9.261

6.  CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.

Authors:  Y Nakajima; S Miyake; K Nagai; T Kawano; T Iwai
Journal:  Jpn J Cancer Res       Date:  2001-12

7.  Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.

Authors:  T C Kok; A Van der Gaast; J Dees; W M Eykenboom; H Van Overhagen; G Stoter; H W Tilanus; T A Splinter
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.